All Activity

Wyoming’s attorney general has determined that the state will not reclassify marijuana under state law in line with a federal rescheduling move by the Trump administration. “The Wyoming Legislature has not legalized medical marijuana, has not approved a state licensed medical marijuana regulatory scheme, or approved of recognizing any other state’s medical marijuana issued licenses,” Attorney General Keith Kautz (R) said on Tuesday. “Therefore, placing marijuana subject to a state medical marijuana license in Schedule III of the Wyoming Controlled Substances Act is inconsistent with the police powers exercised to date by the Wyoming Legislature.” “The question of whether to remove any type of marijuana from Schedule I of the Wyoming Controlled Substances Act is for the Wyoming Legislature and should not be done through the administrative rule making process,” he said. The legislature, however, previously enacted a law that says “if any substance is designated, rescheduled, or deleted as a controlled substance under federal law,” the commissioner of drugs and substances control “shall control the substance under this act in the same manner as federal law” within 30 days. Under state law, the attorney general serves as the commissioner of drugs and substances control and can formally object to the automatic state rescheduling to prevent it from taking place, subject to a public hearing allowing “all interested parties an opportunity to be heard.” Kautz convened a hearing in June to consider the issue, and also accepted public comments via email. “The Commissioner received eight email comments. Four of the comments expressed support of leaving medical marijuana and marijuana products on Schedule I of the Wyoming Controlled Substances Act. Four of the comments supported placing marijuana and medical marijuana on Schedule III of the Wyoming Controlled Substances Act. One person appeared in person at the hearing and provided testimony requesting that the Commissioner leave all marijuana on Schedule I of the Wyoming Controlled Substances Act. All of the comments—both email and in person—were rooted in the important policy considerations surrounding the legalization of marijuana and marijuana products.” The attorney general also noted that “all marijuana products currently approved by the United States Food and Drug Administration are already scheduled consistent with the federal Controlled Substances Act,” citing prescription medications such as dronabinol, Cesamet and Epidiolex. “The Commissioner will continue to appropriately control individual substances as they are approved by the United States Food and Drug Administration.” “After considering all of the comments from interested parties, the Commissioner has determined that all marijuana products, including marijuana subject to a state medical marijuana license, shall remain on Schedule I of the Wyoming Controlled Substances Act,” Kautz’s announcement says. “This decision is final unless altered by statute.” Under an order issued by U.S. Acting Attorney General Todd Blanche in April, marijuana products regulated by a state medical cannabis license immediately moved from Schedule I of the Controlled Substances Act (CSA) to Schedule III, as did any marijuana products that are approved by the Food and Drug Administration (FDA). An administrative hearing now underway is considering broader cannabis rescheduling, including for recreational products. In Wyoming, activists have sough unsuccessfully to put initiatives to legalize medical cannabis and decriminalize marijuana possession on the ballot. State lawmakers have also considered legislation on the issue, but Wyoming remains one of only a handful of states without any legal medical marijuana access. In 2022 the Wyoming House speaker filed a bipartisan decriminalization bill to remove criminal penalties for possessing small amounts of cannabis and replace the state’s current misdemeanor charge with a $100 fine. But that legislation did not receive a vote despite support from top GOP lawmakers. A bill to legalize and regulate cannabis for adult use in Wyoming advanced out of a House committee in 2021, but it did not move further by the end of that session. A poll released in 2020 found that 54 percent of Wyoming residents supported allowing adults in the state “to legally possess marijuana for personal use.” Meanwhile, other states that also don’t have comprehensive medical cannabis programs are also grappling with changes to state marijuana laws that could be trigged by the federal rescheduling action. A GOP senator in South Carolina, for example, said that “medical marijuana is now legal” in the state under a trigger law. In May, the governing body of the Alabama Department of Public Health voted to object to federal rescheduling of marijuana after health officials said they need more time to determine how to implement a change on the state level. Tennessee Gov. Bill Lee (R), meanwhile, signed legislation this session to block an automatic review that could have potentially legalized medical marijuana under state law following the federal rescheduling of the drug. Photo courtesy of Carlos Gracia. The post Wyoming Attorney General Blocks State Marijuana Rescheduling That Would Be Triggered By Trump’s Federal Reform appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

U.S. states that legalize recreational marijuana see personal bankruptcy rates decline—an effect that seems to be associated with reduced arrests that can create compounding financial problems, according to a new study. Researchers looked at data on personal bankruptcy cases, state cannabis laws and FBI crime data from 2001 to 2024, determining that ending cannabis criminalization is linked to improved financial outcomes. The study, published this month in the journal Finance Research Letters, found “evidence consistent with a legal-cost mechanism.” That is, adult-use cannabis legalization “sharply reduces marijuana arrests, and states with larger arrest declines exhibit larger bankruptcy declines.” “U.S. recreational marijuana legalization reduces personal bankruptcy rates. States with larger marijuana-arrest declines see larger bankruptcy declines.” “By reducing households’ exposure to criminal justice costs such as fines and legal fees, [legalization] may ease the acute financial shocks that can tip vulnerable households into insolvency,” the study authors, who are affiliated with Shenzhen University in China, wrote. The average reduction in arrests post-legalization stands at 87 percent “without affecting broader crime rates,” the study points out. Bolstering the study’s key finding, data showed that states where there were larger reductions in cannabis arrests were associated with “larger declines in personal bankruptcy.” “Furthermore, we find that economically stronger states experience more pronounced reductions in bankruptcy following legalization,” the study concluded. “Using state-year panel data from 2001 to 2024, this paper presents evidence that recreational marijuana legalization is associated with a reduction in the personal bankruptcy rate in the United States. This result is stable across a battery of robustness checks. Heterogeneity analysis reveals that the effect is stronger in economically stable states, specifically those with lower baseline unemployment and bankruptcy rate, and higher median household income.” A separate study from 2020 relatedly investigated the impact of legalization on the broader economy, with researchers at the University of Iowa analyzing 9,810 corporations between 1991 and 2017, finding “a multitude of positive effects” after a state enacts medical marijuana laws. “Firms headquartered in marijuana-legalizing states receive higher market valuations, earn higher abnormal stock returns, improve employee productivity, and increase innovation,” the authors said. Photo courtesy of WeedPornDaily. The post Legalizing Marijuana Reduces Personal Bankruptcy Rates As Arrests Decline, Study Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“We should allow adults who choose to buy cannabis to do it in Kansas, and use it safely and responsibly.” By Sherman Smith, Kansas Reflector Cindy Holscher and Ethan Corson on Tuesday both called for the legalization of recreational marijuana in Kansas, separating themselves from other gubernatorial candidates who only support using the drug for medicinal use or oppose legalizing it altogether. The two state senators are seeking the Democratic nomination for governor in the August 4 primary, alongside Overland Park Mayor Curt Skoog, who has said he would focus first on medical needs. Holscher on Tuesday released a video of herself speaking from the parking lot of a dispensary in Missouri, which she said was about 15 minutes from her house in Overland Park. She said the parking lot was full of vehicles with Kansas license plates. Marijuana has been legal for recreational use in Missouri for nearly four years. “That’s a lot of Kansas tax dollars going straight into Missouri’s pocket,” Holscher said. “Most Kansas voters think marijuana should be legal in our state, but because it isn’t, Kansans buy it out of state, and we miss out on the opportunity to raise more money for schools and public services. It’s time for that to change.” As your next governor, I’m ready to legalize cannabis in Kansas. Who’s with me? pic.twitter.com/qhiVM4VziR — Cindy Holscher (@cindy4kansas) July 7, 2026 Corson, meanwhile, issued a statement declaring it was time for Kansas to legalize both medical and recreational marijuana. He pointed out that Kansas is among the few states where marijuana remains completely illegal. “Kansas is falling behind while people suffering from chronic pain, PTSD, cancer, and other serious conditions are denied relief, and tax dollars that could be invested into education here are crossing the border into other states,” Corson said. “As governor, I will support thoughtful legalization, with commonsense guardrails that protect public safety while respecting personal freedom and increasing revenues.” Today, I’m announcing my support for legalizing both medical and recreational marijuana in Kansas. pic.twitter.com/avmlJlORWW — Ethan Corson (@ethancorson) July 7, 2026 On the Republican side, none of the leading candidates supports the legalization of marijuana for any purpose. That includes Senate President Ty Masterson, of Andover, who has blocked medical marijuana legislation from moving forward. The notable exception among the seven Republicans who will be on the primary ballot is Nick Reinecker, a longtime advocate for decriminalizing the drug. “As governor, I will fight to de-schedule cannabis and eliminate criminal penalties for possession and planting,” he said Tuesday. Holscher’s endorsement of recreational marijuana jibes with her willingness to embrace policies that have broad public support, even if they make her an outlier politically. She has called for a moratorium on building data centers, criticized the massive incentives used to lure the Kansas City Chiefs across state lines and voted against a new law that bans cellphones in schools. In the video she released Tuesday, Holscher said Missouri raked in $255 million in cannabis taxes last year. She said legalizing marijuana would help Kansas keep tax dollars that would benefit schools. “We should allow adults who choose to buy cannabis to do it in Kansas, and use it safely and responsibly,” Holscher said. “Legal cannabis is common sense, and it’s time to make it happen.” Last year, a survey conducted by the the Docking Institute of Public Affairs at Fort Hays State University found that 64.8 percent of Kansas adults favor legalizing recreational marijuana, and 70.4 percent support legalizing medical marijuana. During a recent recording of the Kansas Reflector podcast, Skoog said one of his first moves as governor would be to deploy his running mate, Fredonia physician Jennifer Bacani McKenney, to work on a medical marijuana plan. The key, he said, was to regulate it “in a way that is driven by the medical need.” He said he “potentially” could support recreational marijuana sometime down the road. “If we decide to legalize marijuana, the state is in the marijuana business, just like the state is in the alcohol business, and we need to make sure that we have the rules and regulations in place to make sure that criminal elements don’t penetrate into that business, just like we do on the alcohol side,” Skoog said. This story was first published by Kansas Reflector. The post Kansas Democratic Candidates For Governor Campaign On Marijuana Legalization Support appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Thanks for a very interesting blog. What else may I get that kind of info written in such a perfect approach? I’ve a undertaking that I am simply now operating on, and I have been at the look out for such info. 79C

Nice post! This is a very nice blog that I will definitively come back to more times this year! Thanks for informative post. 78N

As a hearing on Trump administration’s federal marijuana rescheduling proposal proceeds this month, a new poll shows that most cannabis consumers aren’t optimistic that reform will be fully implemented by the end of the year. Acting Attorney General Todd Blanche in April issued an order that immediately reclassified state-licensed medical cannabis, as well as marijuana products approved by the Food and Drug Administration (FDA) from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Under a separate order the acting attorney general signed, the ongoing hearing is considering more comprehensively moving marijuana to Schedule III—but the new survey, conducted by cannabis telehealth platform NuggMD, shows that most consumers don’t think that will happen by the time 2026 is over. “In April, medical cannabis was partially rescheduled, moved to a less-restricted category,” the respondents were told. “Now, the federal government is weighing whether to extend that change to all other cannabis, which remained federally prohibited.” “Do you think that will happen by the end of the year?” they were asked. A majority—52.5 percent—said they do not think full cannabis rescheduling will happen by the end of the year, while 47.5 percent said they do expect to see the reform announced by then. The poll involved interviews with 1,063 cannabis consumers who live in state-legal markets from July 2-6 and has a margin of error of +/- 3.01 percentage points. Q: “In April, medical cannabis was partially rescheduled, moved to a less-restricted category. Now, the federal government is weighing whether to extend that change to all other cannabis, which remained federally prohibited. Do you think that will happen by the end of the year?” n: % Yes 505 47.5% No 558 52.5% The ongoing hearing overseen by a Drug Enforcement Administration (DEA) judge is set to conclude by July 15. It’s not entirely clear how long after that the judge will issue his recommendations to the agency—and what the recommendation will be—or how soon after that the DEA administrator will announce a final decision. “Like many, I had doubts when the DEA announced the participants, but early coverage is largely positive, and the testimony the DEA put on record has been more convincing than I think many consumers and stakeholders expected,” NuggMD CEO Charlie Russell told Marijuana Moment, referring to news that the agency has been focusing testimony on the medical benefits of cannabis and its relative safety compared to alcohol and other substances despite excluding reform supporters from participating in the hearing. “Early reports have increased my confidence that the hearing will result in full rescheduling,” he said. Marijuana Moment sent requests to DEA Chief Administrative Law Judge Derek Julius and to Terrance Cole, the DEA administrator, requesting they reverse a decision to prohibit the public from tuning into the cannabis hearing via livestream. A congressman and other journalists later joined in that request, but the agency maintained its ban on streaming. The post Most Marijuana Consumers Don’t Believe Trump Administration Will Complete Rescheduling This Year, Poll Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I was reading some of your content on this website and I conceive this internet site is really informative ! Keep on putting up. 77Z

“THC is a weapon of mass destruction, causing chemical injuries to the brain from the body.” By Stephen Simpson, The Texas Tribune The Texas Senate Committee on Health and Human Services held a public hearing Tuesday to gather information that will shape future legislation on THC products sold in the state. Lawmakers made arguments against THC that harkened back to the days of the “Just Say No” campaigns of the ’80s regarding the risks of THC usage and its effects. Members of the committee used the frying-pan-and-brain analogy as an example of how these products cause mental health problems among young people. The purpose of the meeting was to address the societal impacts of THC product consumption. No decision was made at the meeting because it was meant to be just for analysis. “Nancy [Regan] is the one who started the war on drugs; she was made fun of, and still is today. But you know, she was right. She saw the big picture of how this stuff is so insidious and gets into every fiber of society and every element of family,” said Sen. Charles Perry, R-Lubbock, who confirmed he will once again file a bill to ban consumable hemp products at the next legislative session. A public comment period wasn’t allowed for the sake of time, lawmakers said, although invited members were allowed to speak. Five of the experts who were called to speak by committee members were those who have been vocal against THC products. Invited speakers included Allen Police Chief Steve Dye, who became the face of THC raids, and Aubree Adams, the director of Citizens for Safe and Healthy Texas, who actively campaigns against hemp-derived THC products, citing the risks to youth and mental health. Sen. Lois Kolkhorst, R-Brenham, chair of the committee, said data provided to the state by the Texas Department of Family and Protective Services show that in fiscal year 2024, 1,559 children tested positive at birth for THC, and in 2025, the number increased to 1,896, underscoring the need for change. “I have faith that we can find solutions that will improve our state’s public health and safety, while also respecting the dignity of every Texan who has lost their way due to the fog of mental illness and substance abuse,” she said. “They call fentanyl a weapon of mass destruction. I disagree. Fentanyl is a weapon of mass death. THC is a weapon of mass destruction, causing chemical injuries to the brain from the body,” Adams told the committee. Medical experts and educators from across Texas were also called to speak on cannabis use disorder and the risk of frequent THC usage, with them citing the increasing number of THC-related calls to poison control. “When products became easier to obtain, more people used them, and when more people use them, more people are harmed by them,” said Dr. Matthew Rossheim, an associate professor at the University of North Texas Health Science Center. Katharine Neill Harris, a drug policy fellow at Rice University’s Baker Institute for Public Policy, said some comments from lawmakers conflated issues related to cannabis use with broader challenges related to mental illness, homelessness and youth learning. “For example, THC can increase the risk for psychosis or psychotic episodes in those who are predisposed to or have a history of such conditions. This is different from saying that THC causes psychosis in an otherwise healthy individual,” Harris said. Harris said there are real health concerns related to THC, but affordable treatment must be a topic of conversation if lawmakers want to see real change. “Prevention is ideal. When substance use disorders can’t be prevented, early treatment is the next best option,” she said. “The lack of affordable, accessible, high-quality treatment options in the state increases the likelihood that those with mild substance use disorders will progress to more severe addiction.” The committee meeting took the opposite tone from what state Sen. Nathan Johnson, D-Dallas, and Rep. Drew Darby, R-San Angelo, said earlier this year, when they told cannabis industry leaders at the Texas Cannabis Policy Conference that the attempted ban on consumable hemp opened their eyes to how passionate Texans are about these products. Now it’s time to find a safe and responsible way to regulate businesses that sell THC instead of prohibition, they said. Last year, the Texas Legislature voted to ban the products out of fear that these intoxicating products were consistently getting into the hands of children. But, Gov. Greg Abbott (R) vetoed the decision last summer, before asking the Texas Alcoholic Beverage Commission and DSHS to increase regulations on the industry instead. The Texas Department of State Health Services released regulations on consumable hemp-derived THC products that went into effect on March 31. These new regulations include child-resistant packaging, a significant increase in licensing fees, new labeling, testing, and bookkeeping requirements. The rules also codify the legal purchasing age to 21, which went into effect last year as an emergency directive. Also, under the new rules, laboratory tests now measure the total amount of THC in a product. If THC levels exceed the 0.3% threshold, even if it’s only activated upon being smoked, the product will be noncompliant under state regulations. As a result, some of the most popular hemp products, like THCA flower and pre-rolled joints, have been banned. The rules also increase licensing fees for manufacturers of hemp-derived THC from $258 to $10,000 per facility and retail registrations from $155 to $5,000, which industry leaders say will fulfill the ban by forcing businesses to close. Supporters of the licensing fee increase said this is a necessary step to protect children from hemp products and want more enforcement of penalties on hemp stores that operate without a license. Perry, during the committee meeting, applauded the high licensing fees, suggesting that the goal is to close businesses. “The cost of doing business is going to get so high that most of them will go out of business, I hope,” he said. Perry said those who need these popular THC products need to seek the Christian God because he has reached his breaking point with the hemp industry and will do everything in his power to see them closed down. “Hopefully, you’ve got support, hopefully you’ve got people that have the faith. It’s the good Lord that created us, Christ that saved us, and a spirit that moves us,” he said. Disclosure: Rice University has been a financial supporter of The Texas Tribune, a nonprofit, nonpartisan news organization that is funded in part by donations from members, foundations and corporate sponsors. Financial supporters play no role in The Texas Tribune’s journalism. Find a complete list of them here. This article first appeared on The Texas Tribune. The post Texas Senator Pledges Renewed Effort To Ban Hemp THC Products appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Pennsylvania police officials are being sued over a state law that blocks people with past convictions for possessing marijuana or other illegal drugs from obtaining licenses to carry guns. The new lawsuit, filed in federal court, cites a recent Supreme Court decision to uphold the gun rights of people who use cannabis. U.S. Air Force veteran Craig Philips is suing the acting commissioner of the Pennsylvania State Police and the sheriff of Butler County in their official capacities in carrying out a state policy that denies people with drug convictions, including for simple possession, from obtaining a Pennsylvania License to Carry Firearms (LTCF). According to the complaint, which was filed in conjunction with the Second Amendment advocacy groups Gun Owners of America and Gun Owners Foundation, Philips was convicted of possession of a small amount of cannabis in 1994 and “has not used marijuana or other unlawful drugs” since then, nor has he ever been convicted of any other crimes. Yet under state law he is “permanently ineligible” for a LTCF. While Philips is not prohibited from owning or possessing firearms under state or federal laws, the inability to obtain a LTCF means he is “substantially restricted from carrying or transporting a firearm in a vehicle, carrying a firearm in Philadelphia, carrying a firearm for protection during a declared state of emergency, and exercising the right to bear arms in ordinary public life,” the complaint says. “The denial of Plaintiff Philips’ LTCF therefore burdens not only concealed carry, but the practical ability to bear arms outside the home for lawful self-defense,” it says. Under recent Supreme Court precedent, “historical tradition does not support permanently denying the right to bear arms to a person based upon the nonviolent offense of Possession of a Small Amount of Marijuana occurring over three decades prior,” the filing claims. “No current facts support any finding that Plaintiff Philips is dangerous to himself or others,” it says. “Defendants cannot historically justify that infringement based on a single marijuana conviction from 1994 where Plaintiff Philips has since lived as a law-abiding citizen and remains eligible to possess firearms.” The Supreme Court, for its part, has already started applying its finding in the marijuana and Second Amendment rights case to those involving other cannabis consumers who were prosecuted for possessing firearms. A recent poll, meanwhile, found that most Americans support the Supreme Court’s decision on gun rights for cannabis consumers—including majorities across party lines. Also, a federal agency that regulates guns says it is planning to provide guidance in the wake of the court ruling on the Second Amendment rights of people who use marijuana. Pennsylvania lawmakers, meanwhile, continue to debate whether to legalize recreational marijuana. Read the full lawsuit on gun rights and marijuana convictions below: The post Pennsylvania’s Ban On Gun Licenses Over Marijuana Convictions Is Being Challenged In A New Federal Lawsuit appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Experiencing a one-night stand with a stunning beauty leaves you completely speechless. Every Vasant Vihar Escort we represent possesses insatiable sensuality and flawless looks to die for. We ensure our glamorous companions adapt perfectly to your distinct moods. Choose a curvy hottie for hours of intimacy. Call our agency to schedule a fulfilling experience at affordable rates.

“Medical cannabis patients in recovery deserve the same opportunity for stable housing as any other patient managing a chronic condition with a lawfully prescribed medication.” By Jeremy Tillem, GreenhouseRVA Virginia’s recovery housing system is now forcing legal medical cannabis patients out of stable, certified homes—not because of any new public safety threat, but because a state law passed before cannabis was federally recognized as having accepted medical value refuses to catch up with reality. As of July 1, new certification mandates under Senate Bill 270, which was passed this year, require state-approved recovery residences to prohibit all cannabis use—including doctor-approved medical cannabis that the U.S. Department of Justice officially rescheduled to Schedule III under the Controlled Substances Act (CSA) in April. This creates an immediate, unconstitutional conflict: certified homes for people recovering from substance use disorders must either demand that residents abruptly stop a federally lawful Schedule III medication or risk losing their ability to operate. As a result, residents are left to choose between their prescribed treatment for chronic pain, PTSD, anxiety or other conditions and a roof over their heads. This is not a minor regulatory technicality. Under the Americans with Disabilities Act, individuals using controlled substances are excluded from disability protections only when engaged in the “illegal use of drugs” under the CSA. Because the DOJ has rescheduled state-regulated medical cannabis to Schedule III, it is no longer an illegal drug when used pursuant to a valid state medical recommendation. Forcing cessation of this medication to access housing violates the ADA. The Fair Housing Act likewise prohibits discrimination against people with disabilities in housing. Denying stable housing solely because of a doctor-prescribed, non-combustible medication is textbook discrimination. The inconsistency is glaring. Virginia does not bar residents from taking other Schedule III or Schedule II medications—such as Tylenol with codeine or prescribed opioids—in recovery housing. Selectively targeting only medical cannabis patients under SB 270 is arbitrary and legally indefensible. Virginia’s own code (§ 40.1-27.4) already protects certified medical cannabis patients from discrimination in hospitals, nursing homes and schools. But SB 270, which was sponsored by Sen. Schuyler T. VanValkenburg (D), passed by the Senate and House of Delegates and signed into law by Gov. Abigail Spanberger (D), carves out recovery housing as the sole exception, punishing the very people the system claims to help. The Virginia Association of Recovery Residences (VARR), in turn, has turned this conflict into a trap. Rather than processing applications under the standards that existed when they were filed, VARR slow-rolled reviews while backing and awaiting passage of SB 270’s prohibition language. At GreenhouseRVA, we submitted our complete application for state certification in late 2025. Our policies—which addressed medical cannabis only under strict medical supervision, with appropriate safeguards—were reviewed for months without objection. Then, with no advance notice and no guidance whatsoever on how to come into compliance, we were simply told to withdraw our application to avoid a formal denial, two days before the new law came into effect. VARR offered no advice, no pathway forward, and no opportunity to cure the issue. On our own initiative, we immediately revised every intake document, program policy and resident agreement to remove all cannabis-related language and resubmitted our application. We are currently awaiting their determination. The message to operators across Virginia is unmistakable: harm-reduction and multiple-pathways models have no place in the new certified system, regardless of national standards or federal law. The National Alliance for Recovery Residences (NARR), whose framework VARR purports to follow, explicitly permits certified homes to adopt medical cannabis policies. These include requirements for valid Virginia medical cards, secure lockbox storage, non-combustible administration, inventory controls and clear consequences for misuse. NARR recognizes a basic truth that Virginia’s current framework ignores: for many people in recovery, medical cannabis is a legitimate clinical tool that helps manage symptoms that might otherwise trigger relapse to far more dangerous substances. Instead of supporting evidence-based flexibility, the new certification regime is consolidating power around a single abstinence-only model—the very form of coercive control that recovery housing reform was supposed to prevent. At GreenhouseRVA, we have operated a structured residence since 2021 serving roughly 25 residents at a time, many referred by local court, probation officers and treatment providers. Residents are successfully using doctor-recommended medical cannabis to manage symptoms instead of—or while reducing reliance on—methadone, Suboxone, Xanax and other pharmaceuticals that carry their own serious risks of dependence, side effects and long-term complications. Forcing these individuals off cannabis does not promote recovery or abstinence; it removes a tool many are using to step away from more problematic medications and destabilizes the very progress they have made. Our retention has been strong precisely because we meet people where they are rather than imposing a one-size-fits-all ideology. We understand and appreciate the therapeutic value cannabis can have in a persons recovery process from addiction. Instead of supporting evidence-based flexibility, the new certification regime is consolidating power around a single abstinence-only model—the very form of coercive control that recovery housing reform was supposed to prevent. Forcing homes like ours to close down or abandon medical cannabis accommodations does not protect residents; it destabilizes them and increases the risk of homelessness and relapse. The fix is clear and urgent. The Virginia Department of Behavioral Health and Developmental Services (DBHDS), which SB 270 charges with setting minimum certification standards, should immediately initiate an emergency regulatory review to align the state’s definition of allowable medications with the federal Schedule III reclassification. This would restore operator discretion consistent with federal civil rights law without weakening legitimate oversight. In the 2027 General Assembly session, lawmakers should enact clarifying legislation that explicitly permits NARR-aligned medical cannabis policies in certified recovery residences. Such a measured reform would advance public safety and recovery outcomes, honor federal law and prevent good-faith operators from being punished for following evidence rather than ideology. Recovery is not monolithic. Some paths require total abstinence from all substances. Others incorporate FDA-recognized medications—now including Schedule III medical cannabis—under medical supervision. Virginia’s policies should reflect that clinical reality rather than punish it. Medical cannabis patients in recovery deserve the same opportunity for stable housing as any other patient managing a chronic condition with a lawfully prescribed medication. We are not asking for unregulated or recreational use on property. We are asking for basic consistency with federal law and national best practices. Continuing down the current path will only produce more unnecessary suffering, more evictions from certified housing, and more Virginians forced to choose between their medicine and their home. Jeremy Tillem is the founder and operator of Greenhouse RVA, Virginia’s first structured, cannabis-friendly recovery residence. As a person in long-term recovery from opiate use disorder, he is a dedicated advocate for evidence-based plant medicine models that use cannabis as a tool to combat the opioid epidemic and the broader illicit drug epidemic. The post New Virginia Law Forces Medical Cannabis Patients To Choose Between Their Medicine And Their Housing (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Delhi is a city of dreams, and we're here to make those dreams a reality. Our Call Girls Service in Delhi brings you a curated collection of stunning companions who are passionate about making you happy. From the moment they walk in, you'll feel the chemistry. Our girls are trained in the art of seduction and are ready to explore your deepest desires with you. No judgment, no rush — just pure pleasure. With cash on delivery and free doorstep service, we've made it super easy for you. Call us now and experience the magic in Delhi.

VA marijuana implementation survey; IL cannabis guidance for dispensaries; Poll: THC drinks as alcohol alternative; OR psilocybin fee increase Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Free to read (but not free to produce)! We’re proud of our newsletter and the reporting we publish at Marijuana Moment, and we’re happy to provide it for free. But it takes a lot of work and resources to make this happen. If you value Marijuana Moment, invest in our success on Patreon so we can expand our coverage and more readers can benefit: https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The National Institute of Standards and Technology published a report aimed at helping state marijuana regulators “develop a set of requirements for scales used in the sale of Cannabis products, based on scientific analysis.” “Cannabis products are unique in that they have distinct properties from traditional commodities that are subject to weights and measures regulations, such as grocery products, precious metals, and gems.” The Virginia Cannabis Control Authority is conducting a survey to gather input from the public and stakeholders as officials work to implement the state’s newly enacted law legalizing recreational marijuana sales. The Illinois Department of Financial and Professional Regulation published guidance for marijuana businesses about newly increased cannabis possession limits and the ability to add drive-thru windows and expand hours of operations. A new poll shows that three out of four people who have tried THC-infused cannabis beverages are reducing their alcohol drinking—with a fifth saying they have quit alcohol altogether. The Oregon Health Authority is moving to significantly increase fees for psilocybin services businesses and to eliminate reduced fees for nonprofits, veterans and low-income people. / FEDERAL The Drug Enforcement Administration sent a notice commemorating the 53rd anniversary of the agency’s founding. / STATES U.S. Virgin Islands Gov. Albert Bryan Jr. (D) cited his prior signing of a marijuana legalization bill in a press release about issuing a proclamation to recognize Ras Tafari Day. Former Florida Democratic gubernatorial candidate Andrew Gillum was arrested for possessing marijuana, dangerous drugs and drug paraphernalia. The Michigan Supreme Court ruled that trial courts can no longer ban marijuana use as a condition of probation. Idaho regulators are moving to amend hemp rules. Montana Fish, Wildlife & Parks is using marijuana revenue to fund animal tracking radio towers. California regulators sent updates about various cannabis issues. The U.S. Virgin Islands Cannabis Advisory Board will meet on July 23. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL The Missoula, Montana City Council approved a moratorium on new recreational marijuana dispensary licenses. Osseo, Minnesota officials will hold a town hall meeting about a proposed municipal cannabis dispensary project on Thursday. / INTERNATIONAL A Thai lawmaker filed a bill to restrict legal cannabis to medical use. Steinbach and Winkler, Manitoba, Canada voters are likely to see questions to end bans on cannabis retail stores on their October ballots. / SCIENCE & HEALTH A review concluded that “CBD has demonstrated anti-inflammatory, neuroprotective, anxiolytic, and analgesic properties, which are potentially beneficial for athlete recovery.” A study found that “buccal administration of THC-[nanoemulsion] represents a promising patient-friendly approach for cannabis-based therapy, offering improved solubility, controlled release and meaningful clinical benefit in patients with refractory chronic pain.” / BUSINESS Glass House Brands Inc. completed its first international sale of smokable CBD biomass to Europe. / CULTURE Neil deGrasse Tyson discussed his reluctance to use psychedelics. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Chris Wallis // Side Pocket Images. The post Feds issue report on cannabis scales to help state officials set rules (Newsletter: July 8, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Really We study this the other day however I'd a few ideas about this now I needed to see this once again simply because it's very well crafted. 맞고사이트

That you're allowed to place leaders, however is not one way links, except when they're just authorised together with regarding niche. AK 게임

126. Psychedelics & Addiction: What the Research Shows Addiction psychiatrist Dr. Nathan Sackett on psilocybin, ibogaine, MDMA, ketamine, and what psychedelic-assisted therapy can and cannot do for substance use disorder. Episode Summary The conversation about psychedelics as addiction treatment is moving faster than the research. Dr. Nathan Sackett is trying to close that gap. Founding director of the Center for Novel Therapeutics at the University of Washington, Sackett is an addiction psychiatrist who still sees patients — which matters, because every study his center runs is rooted in clinical reality, not advocacy optics. In this live recording from the Psychedelic Salon at Town Hall Seattle, we cover what the evidence actually supports, what compounds carry genuine risk, and why the most important variable in treatment outcomes may not be the drug at all. If you've been following psychedelic news and want a clearer picture of what's real, this is the conversation. Key Takeaways Psilocybin works as an accelerant, not a cure. It amplifies therapeutic work already in progress — which means the therapeutic work has to be there first. Ibogaine's cardiac risk is real and cannot be fully predicted even in pre-screened patients. Clinical monitoring with a cardiologist present is not optional — it is the protocol. Ketamine is habit-forming in a way classic psychedelics are not. Since the pandemic, Dr. Sackett has seen a meaningful rise in ketamine use disorder in his clinical practice. The variation in long-term outcomes across psilocybin trials may have more to do with integration therapy than with the drug. The field does not yet have standardized integration protocols. Kratom is available at corner stores and gas stations nationwide and contains a compound with opiate-like properties roughly ten times more potent than morphine. It is undersupported in the research literature and underrecognized as a dependence risk. Timestamps [00:00] Welcome and standard disclaimer [00:00] Intro: Dr. Sackett's origin story — clinical disillusionment, a patient who'd been to a retreat, and how that led to building UW's Center for Novel Therapeutics [00:04] Why the center's name doesn't include the word "psychedelic" — and why that was a deliberate political and scientific choice [00:05] The study no pharma company would fund: psilocybin for co-occurring PTSD and alcohol use disorder [00:07] Why psilocybin over ketamine — metacognition, intensity, and the diversity of themes that come up during the experience [00:08] April's bridge: metacognition, the default mode network, and the practice of cultivating the witness [00:09] Ketamine: legal, widely available, genuinely useful for some — and increasingly implicated in use disorder since the pandemic [00:11] The Psychedelic Education and Harm Reduction Clinic at UW: what a risk triage consult actually looks like [00:13] Benzos and alcohol use disorder since the pandemic — and why women are prescribed benzos at twice the rate of men [00:14] April's bridge: benzo pharmacology, cognitive risk in older women, the Ashton Manual, and who to contact before tapering [00:14] Ibogaine: mechanism, cardiac risk, and the ethics of risk tolerance when the disease itself is fatal [00:18] April's bridge: QTc interval, torsades de pointes, and why cardiac screening is the difference between a high-risk intervention with oversight and a dangerous one without it [00:19] Ayahuasca and polysubstance use — why DMT's unusual craving-reduction profile makes it a candidate for trans-diagnostic research [00:20] Cannabis as a case study: what legalization revealed about the gap between adoption and safety data, and whether psychedelics are on the same trajectory [00:25] State psilocybin programs: Oregon's safety data, New Mexico's prescribed access model, and what happens to state programs once FDA approval arrives [00:28] Synthetic psilocybin vs. whole-plant extraction — and why onset, duration, and clinical experience may differ between the two [00:29] April's bridge: the entourage effect, Filament Health, and what we still don't know about whole-plant vs. isolated compound delivery [00:30] The current UW trial: veterans and first responders with PTSD and alcohol use disorder, a single dose, and what the results look like so far [00:32] The real cost of running a psychedelic trial: $2.5 million, 1,000 people screened for 12 participants, and the funding crisis threatening to stop this research before it reaches the people who need it [00:34] Psychosis and psychedelics: screening practices, genetic load, and why European researchers are beginning to study this in populations previously excluded from trials [00:36] Integration variability: whether differences in long-term outcomes across trials reflect the drug or the therapy model [00:37] MDMA and the FDA: what actually happened, why the boundary violations mattered, and why the agency's hesitation was not irrational [00:40] Which psychedelics for which disorders — and why MDMA and psilocybin may be suited for meaningfully different indications [00:41] Psilocybin vs. ayahuasca vs. ibogaine: mechanism, receptor profile, and experiential differences explained for a general audience [00:42] What psychedelic-assisted psychotherapy actually looks like: prep sessions, the medicine session, integration, and the role of the therapist [00:44] Psilocybin for ADHD and depression: where the pipeline stands and what "mainstream" means when FDA approval is roughly 18 months away [00:46] Safeguards for people in recovery: expectation management, the role of abstinence-based traditions, and why psychedelics are not a way to sidestep behavioral work [00:47] Seattle NTC clinical trial site — open for enrollment; link in show notes [00:48] Fentanyl, street-level opiate use, and what it would take to bring these interventions to people without housing or stable income [00:49] Integrating psychedelic therapy into abstinence-based recovery culture — and why pitting the two against each other serves no one [00:50] Kratom use disorder, ibogaine for kratom withdrawal, and the opiate pharmacology of a plant you can buy at any gas station right now [00:52] April on kratom: what she's observed since 2007 and what the popular podcast conversation gets wrong [00:52] Kratom and serotonin syndrome: what trusted sources exist, what Erowid covers, and where the drug interaction literature actually runs out [00:54] MDMA for relational trauma: why Dr. Sackett is drawn to psilocybin for the PTSD-alcohol intersection and where MDMA research goes from here [00:55] Outro: accelerant, not cure — what that distinction requires of us, of the field, and of the funding structures keeping this research alive Guest Dr. Nathan Sackett is an addiction psychiatrist and the founding director of the Center for Novel Therapeutics at the University of Washington, where he leads clinical research at the intersection of psychedelic-assisted therapy, trauma, and substance use disorder. He sees patients in both an addictions clinic and UW's Psychedelic Education and Harm Reduction Clinic. Dr. Sackett on LinkedIn Center for Novel Therapeutics, University of Washington Resources #46 Cultivating the Witness with Natasha Lannerd — on metacognition, integration, and the internal observer that makes psychedelic work stick #117 Ibogaine Treatment at Beond — a conversation with the co-founders of the Mexico-based clinic whose cardiac data Dr. Sackett is currently studying Ask April: Q: Does the president's executive order legalize psychedelics? — on the executive order, fast-tracked FDA review, and what access will actually cost patients Follow April on Substack Visit aprilpride.com Original Substack post: https://aprilpride.substack.com/psychedelics-addiction-research-nathan-sackett Hosted by April Pride IG: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@aprilpridecreates YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@aprilpridecreates Get full access to APRIL PRIDE at aprilpride.substack.com/subscribeCatch the full episode here

Illinois officials have published guidance for marijuana businesses about a new law that doubles the amount of marijuana that adults can legally possess, allows drive-thrus and curbside pickups at dispensaries and lets them stay open for longer hours of operation, among other changes. The reforms are part of a large-scale cannabis omnibus bill that Gov. JB Pritzker (D) signed into law last month. The Illinois Department of Financial and Professional Regulation (IDFPR), which regulates adult-use and medical cannabis dispensaries, published the five-page explanation of some of the key changes included in the legislation that dispensaries need to know about. “Dispensaries may begin offering curbside pick-up and drive-through services. However, prior to offering drive-through or curbside, licensees need to have their systems reviewed and approved by IDFPR,” it says. “Dispensaries may expand their hours of operations to 2am with local municipal approval.” As enacted into law, SB 3222 allows residents of the state who are over 21 years of age to possess up to 60 grams of marijuana flower—double the amount in prior law. They are also able to have up to 10 grams of cannabis concentrates and infused products with up to 1,000 mg of THC—also double the earlier limit. Possession amounts for adult non-residents are also doubled under the bill and are generally set at half of what residents can carry.. “Additionally, registered medical patients in Illinois are authorized to purchase seeds from licensed dispensaries,” IDFPR said. Among other changes that IDFPR flagged are that: The specific dispensary name is no longer required to be included on cannabis products prior to sale. Dispensaries are no longer required to contract with third party security companies, and instead may hire their own security guards. Dispensaries may begin storing sixty (60) days of security footage rather than ninety (90) days. Agents, agents-in-charge, and principal officers who previously were barred from holding a medical cannabis license solely due to a criminal conviction referred to as an “excluded offense” are no longer barred from holding such license. This is also true of future applicants. Most of the changes in the legislation took effect immediately, but the IDFPR guidance notes that a provision allowing all licensed dispensaries to opt-in for medical licenses will go into force on September 10. “Any adult use dispensary holding an active license in good standing may opt-in for a medical dispensary license,” it said. “This medical dispensary license will allow the dispensary to sell cannabis to medical cannabis patients at the medical tax rate up to the medical patient’s allotment.” Also as of September 10, “all cannabis products sold to medical cannabis patients must contain a federally mandated warning label,” IDFPR said. “This label must be applied prior to the sale to the patient and dispensaries are responsible for ensuring the label is properly affixed to the product.” The agency also noted the loosening of requirements for dispensary employee badges and on marijuana business ownership limits. “This fact sheet is informational only, non-exhaustive, and should not be construed as legal advice, administrative rulemaking, or making binding statements of law,” the guidance, which was first reported by Illinois New Joint, says. “The Department of Financial and Professional Regulation recommends all licensees coordinate with their own legal counsel and comprehensively review all relevant laws and regulations to ensure continued compliance.” IDFPR noted that many of the new changes may require updates to the state’s seed-to-sale tracking system, adding that it is considering hosting a potential town hall meeting on the changes and is “reviewing its existing administrative rules and anticipates proposing any rules needed because of SB 3222 through the formal rulemaking process in the coming months.” The new law also contains a number of cannabis policy updates that don’t directly impact dispensary operations and weren’t noted in the IDFPR guidance. For example, people with past convictions for possession of up to 60 grams of marijuana will now be able to have those records expunged—double the previous cutoff allowing only those with convictions for up to 30 grams to be eligible. The legislation also recriminalizes hemp THC products with more than 0.4 milligrams of THC per container, in line with a federal ban that is set to take effect in November. The state’s list of medical marijuana qualifying conditions is also being expanded to add female orgasmic disorder, endometriosis, ovarian cysts and uterine fibroids. The governor held a signing ceremony for the legislation at a marijuana dispensary, saying he is “proud that Illinois continues to lead the nation in showing what thoughtful, balanced cannabis policy can achieve.” In 2019, Pritzker signed the state’s initial marijuana legalization policy into law. The post Illinois Officials Update Marijuana Dispensaries On Increased Possession Limits And Ability To Add Drive-Thru Windows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“I don’t think the industry can survive this. I think [what] you’re going to see over the next couple years is a major contraction to where there’s just a few people surviving.” By Jake Thomas, Oregon Capital Chronicle State regulators are seeking steep fee hikes on Oregon’s nascent psilocybin industry, a move that critics say would push the already high price tag of a legal mushroom trip even higher while causing more businesses to close. The Oregon Health Authority in late June announced proposed fee increases that would affect virtually every corner of the industry, aiming to financially sustain the groundbreaking program. Among the biggest changes would be doubling annual license fees from $10,000 to $20,000 for psilocybin manufacturers and service centers where adults 21 and older take supervised trips. The potential fee increases come after a wave of service center closures, raising doubts about the viability of Oregon’s legal psilocybin experiment that voters approved in 2020. The state has issued licenses to 39 service centers, about half of which have expired or been surrendered, according to state figures. “I don’t think the industry can survive this,” said Ryan Reid, the co-founder and operations director of Bendable Therapy, a Bend-based service center. “I think [what] you’re going to see over the next couple years is a major contraction to where there’s just a few people surviving.” Oregon’s psilocybin program is not supported by taxpayer money and is instead funded through fees, health authority spokesperson Erica Heartquist said in an email. Because revenue has not kept up with rising costs, she continued, “the only option is increasing fees” despite the program’s cost-saving efforts. Heidi Pendergast, Oregon director of the Healing Advocacy Fund, which advocates for psilocybin access, called the proposed fee increases “unprecedented” and out of line with other licensing costs for the cannabis businesses and health-oriented professions. An individual psilocybin session can cost between $850 and $3,000, which has meant clients have skewed white and wealthier. Pendergast said she anticipates clients would see higher costs from the fee increases, which would mostly take effect next year. The uncertainty comes as psilocybin continues gaining acceptance as a mental health treatment and as the state has opened the door to integrating it with the medical system. Pendergast described the program as safe, noting that just a sliver of the estimated 22,000 people who have used legal psilocybin have reported adverse events since service centers opened in 2023. “This program really deserves to be part of the behavioral health framework in this country,” she said. One licensed lab As the head of Rose City Laboratories, Daniel Huson oversees Oregon’s only licensed and accredited psilocybin testing laboratory. Despite being a linchpin in the state’s psilocybin system, he said the $26,000 his lab made last year from compliance testing didn’t cover all of its costs, including the $10,000 annual licensing fee. Huson continued offering the testing because he’s passionate about how psilocybin can positively change people’s lives. Regulators are seeking to double the annual laboratory licensing fee starting January 2029, later than the other hikes. Since the lab began testing psilocybin in 2023, Huson said he’s increased the cost of a compliance test from $250 to $600, which he expects to rise further. Without a regulatory change of course, he said the industry may not be viable over the next two years and his lab will stop offering psilocybin testing in 2029, potentially leaving the state without a psilocybin testing lab. “There’s no incentive to be a testing laboratory because it’s expensive,” he said. “And they’re going to be in trouble.” No more discounts The proposed changes would also eliminate reduced fees for nonprofits, veterans and low-income people. Currently, each pays half the annual fee for a manufacturer or service center license. If regulators’ proposed changes take effect, those license holders would see their licensing fees quadruple to $20,000. Nearly a third of Oregon’s roughly 400 psilocybin-related licenses qualify for a reduced fee, according to the health authority’s Heartquist. As a nonprofit service center, Bendable Therapy is focused on accessibility over its margins, said Reid, one of its co-founders. The elimination of reduced fees, he said, would mean increased costs for clients and less money for scholarships to make its services more affordable. “This is a tight industry, and we’ve done a good job surviving,” he said. “But this is just going to make it that much harder and just really increase the costs and reduce access for our customers.” Facilitators, who guide clients through psilocybin sessions, would see their annual licensing fees double to $4,000—with discounts for veterans and low-income applicants eliminated. They typically work part-time as contractors. Reid said his center will subsidize the licensing costs of the centers’ six facilitators. Plus, regulators’ changes would increase the cost of a permit needed to work in a center from $25 to $200. In total, he expects licensing costs to increase by as much as $50,000. Campaign promise The ballot initiative campaign that legalized psilocybin in Oregon promised to make the life-altering substance safe, accessible and affordable—without ongoing costs to taxpayers after a startup period. However, a health authority budget document states the industry’s slow growth has meant it hasn’t generated enough license fees to cover the program’s cost. The authority blamed local restrictions on psilocybin-related businesses, as well as challenges getting banking and insurance for an industry centered on a federally illegal drug. It also blamed unexpected administrative costs. Pendergast, of the Healing Advocacy Fund, said it’s common for new programs to require additional funding before they are self-sustaining and called for more budget transparency before the fees increase. “This is really a matter of how we are right-sizing regulation for this program,” she said. Dr. Eric Lee started Space Psychedelic Clinic in 2024 on what he called a “shoestring” budget in “not a gorgeous location” in Portland that allows him to charge $925 for an individual session. He expects to weather the fee increase and plans to move into a larger building to accommodate demand. But he doesn’t think other centers will survive and wants other states considering legal psilocybin to take note of what’s happening in Oregon. “There is a vast segment of the population that will just never be able to use legal psychedelics because of the price point,” he said, adding, “I don’t think people want that from this law, and I think it’s a huge part of why the business is failing.” This story was first published by Oregon Capital Chronicle. The post Oregon Officials Propose Major Fee Hike For Psilocybin Businesses appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A federal agency has published a new report that aims to assist state marijuana officials in developing standards for scales used in the sale of cannabis products. The 31-page document, published late last month by the National Institute of Standards and Technology (NIST), notes that “with the legalization of Cannabis in many States, the suitability of the scales used in the sale of Cannabis products becomes increasingly important.” “Cannabis products are unique in that they have distinct properties from traditional commodities that are subject to weights and measures regulations, such as grocery products, precious metals, and gems,” it says. The report details what NIST believes to be the five most relevant aspects of scales involved in marijuana sales. “These scale characteristics include the accuracy classification, the value of the verification scale interval, the monetary value per scale division, auxiliary indication, and the minimum capacity and recommended minimum load,” it says. When it comes to accuracy classification, the NIST report notes that while it may be reasonable to conclude that scales used for marijuana should be of accuracy Class II because cannabis products “are high-value commodities like precious metals and gems,” the effect of air buoyancy and varying moisture levels “may not justify” the use such high-precision instruments with strict error margins. “Jurisdictions should consider this duality when determining the proper accuracy class for scales used in the sale of Cannabis products,” it says. With respect to monetary value per scale division, NIST says its handbook currently has no requirement on the topic. “If desired, such a requirement could be implemented as a User Requirement for all commodities (or all high-value commodities) to avoid being arbitrary towards Cannabis products,” the report says. For auxiliary indications, which allow higher resolution digits for more precise weighing, NIST said it is a “useful feature that extends the weighing range at the low end” but that it could potentially confuse some consumers. The value of the verification scale interval, minimum capacity and recommended minimum load are interrelated, the report explains. “The recommended minimum load (or minimum capacity) implicitly sets an upper limit on the verification scale interval,” it says. “A separate requirement for a maximum value of the verification scale interval, applied only to scales used for the sale of Cannabis products, appears arbitrary (since there is no such requirement for other high-value commodities in NIST Handbook 44). It also undermines the purpose of the recommended minimum load requirement.” While NIST stresses in the report that it does not promote specific recommendations for states when it comes to requirements for scales used to measure cannabis, its analysis is meant to provide “objective information” that regulators can use to act on the issue. “These conclusions are intended to clarify the discussion and help regulators and other stakeholders develop a set of requirements for scales used in the sale of Cannabis products, based on scientific analysis.” To reach the report’s conclusions, NIST officials examined “real-world data” on scales that are being used to weigh cannabis in nine states. The new document represents the latest in a series of cannabis-related projects for the federal agency. Last month NIST announced that it added dozens of new marijuana components to an official government library of compounds that is used to help identify unknown substances in food, drugs, cosmetics, the environment, body fluids and forensic evidence. In 2025, NIST hosted a workshop aimed at facilitating “an open and candid discussion” about the development and implementation of technology to test a person’s breath for marijuana impairment. Also last year, researchers with the agency said they made the first-ever detection of THC in human breath following the consumption of infused edibles—a possible step forward in terms of field testing for cannabis impairment. NIST has also published a series of reports as part of a project called the Cannabis Laboratory Quality Assurance Program (CannaQAP). Meanwhile, NIST has made a series of updates to an industry standardization handbook it publishes as a result of cannabis-related stances adopted by the National Conference of Weights and Measures. The post New Federal Report Analyzes Scales Used To Weigh Marijuana, Offering Advice For State Officials appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A new survey shows that more than three out of four people who consume THC-infused cannabis beverages drink less alcohol—with more than a fifth saying they have quit alcohol entirely. The poll, published on Tuesday, was conducted by THC beverage company Crescent Canna, which surveyed its customers about their use of THC drinks. Since first trying the products, 37 percent said they drink much less alcohol, 19 percent drink slightly less and 21 percent have quit alcohol altogether. Forty-four percent said that THC beverages have become part of their regular wellness routine. When asked more specifically why they like cannabis drinks, 80 percent said the products help them relax or unwind and 50 percent said they use them as a sleep aid. More than half (51 percent) said THC beverages help them to avoid the negative effect of alcohol, and 60 percent said there is no hangover. Via Crescent Canna. More than a third of THC drink consumers (35 percent) said they end up using other cannabis products less often due to the availability of the beverages. Another 15 percent said they exclusively consume cannabis in drink form. Consumers, meanwhile, are broadly aware of the looming federal recriminalization of hemp-derived THC products that is set to take effect in November, with 87 percent saying they know about the planned ban. Twenty-seven percent said they are either actively stocking up on THC drinks or buying them more often in preparation for the federal crackdown, and another 41 percent said they plan to as November approaches. If the ban goes into effect as scheduled, 67 percent of THC drink consumers said they would turn to other forms of cannabis and 23 percent would start drinking more alcohol. Just 8 percent say they would stop using THC entirely. For now, the vast majority of consumers (63 percent) say they are buying cannabis drinks online, while another 26 percent say they obtain them at grocery, liquor, convenience or specialty retail stores. Five percent get THC drinks at marijuana dispensaries and another 5 percent buy them at bars, restaurants or event venues. The poll involved interviews between May 29 and June 11 with 1,637 adults over the age of 21 who have tried a THC beverage at least once. An earlier poll conducted by Crescent Canna last year similarly showed that nearly four in five adults who drink cannabis-infused beverages say they’ve reduced their alcohol intake—and more than a fifth have quit drinking alcohol altogether. A separate recent survey from cannabis telehealth platform NuggMD found that marijuana consumers shows they are overwhelmingly more likely to want to dine at restaurants that offer cannabis-derived THC drinks as an alternative to alcohol. A previous NuggMD poll found that cannabis consumers are more likely to shop at Target following the major retailer’s decision to start selling hemp-derived THC drinks, The latest poll results on consumer preferences come as lawmakers from both major parties have filed various pieces of legislation to delay, alter or reverse the impending federal recriminalization of hemp THC products and as the White House pushes Congress to act on the issue. Hemp derivatives with less than 0.3 percent delta-9 THC on a dry-weight basis were federally legalized under the 2018 Farm Bill that President Donald Trump signed during his first term in office. But late last year, he signed new legislation containing provisions that will redefine hemp to make it so only products with 0.4 milligrams of total THC per container will remain legal after November 12. In a letter to House Speaker Mike Johnson (R-LA) last month, White House Office of Management and Budget (OMB) Director Russell Vought said the administration wants lawmakers to “ensure the fair treatment of hemp products”—specifically citing legislation that would keep many hemp products legal that are currently set to be recriminalized this year, add labeling requirements and institute new taxes on sales, among other regulatory reforms. The administration “welcomes the opportunity to work with the Congress to, at a minimum, update the statutory definition of final hemp-derived cannabinoid products to allow Americans to benefit from access to appropriate full-spectrum CBD products,” OMB separately said last month, “while preserving the Congress’s intent to restrict the sale of products that pose serious health risks.” The call to avert a broad prohibition on hemp CBD products was included in a statement of administration policy about an annual agriculture spending bill that passed the House of Representatives. Several lawmakers had filed amendments to that legislation to keep hemp products legal, but each was either blocked by the House Rules Committee from advancing to a floor vote or withdrawn by its sponsor. “The Administration supports advancement of this legislation, but looks forward to addressing its concerns prior to enactment,” OMB said in its statement of administration policy. “The Administration looks forward to working with the Congress to provide more input as the bill’s legislative process unfolds.” In April, the president himself urged congressional lawmakers to again redefine hemp to avoid recriminalization of full-spectrum CBD products. “I am calling on Congress to update the Law to ensure that Americans can continue to access the full-spectrum CBD products they have come to rely on, and that help them, while preserving Congress’s intent to restrict the sale of products that pose Health risks,” Trump said in a Truth Social post on the same day his administration announced it is moving forward with rescheduling marijuana. “We must get this done RIGHT and FAST, especially for those who saw that CBD helps them,” he said. “Plus, I am told it will also help our GREAT FARMERS, who we love, and will always be there for.” Industry advocates say that the law as enacted last year not only threatens to prohibit intoxicating and synthetic cannabinoid products but also stands to remove popular full-spectrum CBD products that many Americans use therapeutically from the market. “ONE in FIVE adults used it in the past year, and many say it improved their chronic pain enormously,” the president said in his social media post, adding that hemp-derived CBD “has made a HUGE difference for so many people.” He also referenced a new initiative the administration launched in April to cover up to $500 worth of hemp-derived products each year for eligible Medicare patients. The program being implemented by the Centers for Medicare & Medicaid Services (CMS) focuses largely on CBD but also allows products to have up to 3 milligrams of total THC per serving. “In December, I signed a very important Executive Order calling for Research and Innovation for Hemp-derived CBD,” Trump said. “Our wonderful Dr. Mehmet Oz moved fast to follow the directive in the Executive Order, and launched a model for some Seniors earlier this month. But more must be done!” “Please get it done, and SOON,” the president said in reference to a congressional fix for the broad recriminalization set to take effect in November. “Thank you for your attention to this matter!” It’s not clear how far Trump wants to scale back the scope of the scheduled federal restrictions on hemp products and what kinds of revised THC rules and limitations he would prefer to sign into law. As Marijuana Moment reported last month, a Republican congresswoman is circulating draft legislation that would keep hemp THC beverages legal under federal law, creating a carve-out from the broad recriminalization of products derived from the crop that is set to take effect later this year. The Hemp-Derived Beverage Regulatory Clarity Act from Rep. Beth Van Duyne (R-TX), in its current form, would allow adults over 21 to purchase and consume hemp THC drinks with up to 5 milligrams of delta-9 THC per serving. It would also impose a federal tax of 10 cents per milligram of any hemp-derived cannabinoid contained within such beverages. The National Restaurant Association, which represents the industry, recently sent a letter urging congressional leaders to delay the federal recriminalization of hemp THC beverages that is scheduled to take effect later this year and replace it with a regulatory framework that “ensures consumer safety while meeting growing market demand” for the products as an alternative to alcohol. A U.S. Department of Agriculture report published in April shows that farmers in the U.S. grew three-quarters of a billion dollars worth of hemp crops in 2025—a 64 percent increase from the prior year. The post THC-Infused Cannabis Beverages Are Helping People Quit Drinking Alcohol, Survey Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Excellent post. I was always checking this blog, and I’m impressed! Extremely useful info specially the last part, I care for such information a lot. I was exploring this particular info for a long time. Thanks to this blog my exploration has ended. agen toto

Excellent post. I was always checking this blog, and I’m impressed! Extremely useful info specially the last part, I care for such information a lot. I was exploring this particular info for a long time. Thanks to this blog my exploration has ended. bmw777 login

Tired of spending your evenings alone in Delhi's bustling surroundings? It's time to change that! Our agency is known for its reliability, discretion, and top-notch service. Our Delhi Escort service offers you a chance to meet some of the most beautiful and exciting women in the capital. Whether you're looking for a quick fling or a long, passionate night, our girls are ready to deliver. With 1500+ profiles to choose from, including college girls, models, and housewives, we have something for everyone. Book now and get free delivery within 30 minutes. Your perfect evening in Delhi starts here. Lutyens Escort || Escort in Maharani Bagh || Malviya Nagar Escort Service || Escort Service Bengali Market || Escort Service in Mandi House ||

Some truly wonderful work on behalf of the owner of this internet site , perfectly great articles . bmw777

Marijuana regulators in Virginia are conducting a survey to gather input from the public and stakeholders as they work to implement the state’s newly enacted law legalizing recreational cannabis sales. The Virginia Cannabis Control Authority (CCA), which currently oversees medical cannabis and under the new law will also regulate adult-use marijuana and hemp, said the survey “is designed to bring real-world insight from people and organizations who are part of, or impacted by, Virginia’s evolving cannabis market.” “Feedback collected will help the CCA better understand a range of perspectives and will inform ongoing planning and decision-making as it considers future regulations,” CCA said. Respondents are given an open-ended field to enter in comments after choosing a broad topic area, including: Fees and Retail License Applications License, Permits, and Registrations (e.g., impact and microbusiness) Security: Facility and Personnel Advertising, Transportation, and Other Regulated Operations Labeling and Packaging Cannabis Products Regulated Product Testing Compliance and Enforcement (Related to licenses and sales) Regulated Hemp Products Public Health & Safety Other “This is about making sure we hear directly from the people who are closest to the work and the impacts,” Jamie Patten, the acting head and chief administrative officer of CCA, said in a press release. “Stakeholder feedback is an important part of our process as we work to develop regulations that protect public safety, advance public health, and support a well-regulated cannabis market.” Your voice matters. The CCA is seeking feedback on future cannabis regulations through a new survey. Share your perspective to help inform the CCA of potential regulation impacts. Fill out the form: https://t.co/evY70cBqdh pic.twitter.com/7kyfHHa4BH — Virginia Cannabis Control Authority (@Virginia_CCA) June 30, 2026 “Your input will enable the CCA to consider how any future regulations may impact varying stakeholders,” the form says. “We value all input and while the CCA cannot implement every suggestion, we are tracking all ideas for the future.” The survey is available through July 21. CCA separately posted a brief explainer of the key provisions of the state’s newly enacted marijuana laws. New marijuana and hemp laws are coming to Virginia. Wondering what changes, when they take effect, and what they mean? We've broken it all down in one place. Read the overview: https://t.co/zAUYDub1Kt@VaAgriculture — Virginia Cannabis Control Authority (@Virginia_CCA) July 1, 2026 Late last month, the Virginia Senate and House of Delegates adopted Gov. Abigail Spanberger’s (D) proposed amendments to budget legislation containing provisions to legalize recreational cannabis sales that they had given initial approval to previously. Because lawmakers accepted her suggested changes in full, the measure was immediately formally enacted into law and didn’t require any further action from the governor. Spanberger in May vetoed a previous measure to legalize recreational cannabis sales after lawmakers rejected her proposed amendments to the plan. She later negotiated with Sen. Lashrecse Aird (D) and Del. Paul Krizek (D), who sponsored the earlier measure, on a compromise deal that was included in the budget legislation that passed. The new plan differs significantly in several ways from the earlier legislation. For example, it sets the launch date for recreational marijuana sales at July 1, 2027, which is what Spanberger proposed in contrast to the January 1 date in what lawmakers had passed. It also sets the legal public marijuana possession and per-transaction purchase limit at 2 ounces, an increase from the current legal limit of one ounce. The legislation lawmakers passed earlier this year would have allowed adults to possess up to 2.5 ounces. The bill also cedes to Spanberger on language to increase a marijuana excise tax from 6 percent to 8 percent after two years of legal sales. By way of compromise, the new agreement will make public consumption of marijuana punishable by a civil penalty of $250—a significant increase from the $25 in current law but less harsh than the class 4 criminal misdemeanor the governor sought in her proposed changes to the previous bill. Lawmakers passed the initial cannabis sales bills in March, but the governor then suggested changes to the legalization proposal—including delaying the start date for sales by six months, increasing taxes and instituting new criminal penalties for cannabis consumers. The legislature in April declined to take up the amendments during a one-day reconvened session, however, effectively rejecting them. Spanberger then issued a veto. Spanberger said in June that she was having “really productive” and “incredible” conversations with lawmakers about crafting a compromise approach to legalizing adult-use cannabis sales, and Marijuana Moment previously reported on the ongoing talks. The governor, meanwhile, has tried to publicly explain her veto—including by saying it is her view that “taking a little bit longer” to launch the market is not something she sees as “negative” because it is more important to get the details right than to do it fast. A recent survey found that bipartisan majorities of Virginia voters wanted Spanberger to sign the cannabis legislation into law, and that they specifically disagreed with her desire to slow the launch timeline for legal sales. The governor recently acknowledged in a separate interview that “a lot of people are not pleased” with her veto of the cannabis legislation. “Friends and family are displeased as well,” she said. Spanberger has repeatedly responded to criticism of her cannabis amendments from the bill sponsors and advocates by saying the suggested changes came after she spoke to the leaders of other states that have already implemented adult-use marijuana markets. A spokesperson for Spanberger declined to name any other governors she talked to about cannabis in response to a question from Marijuana Moment, however. The governor separately sought to explain her veto in an earlier interview, reiterating that she supports launching a legal cannabis market but worried about what she called a “rushed timeline” and “far more stores across Virginia” than she thinks are appropriate. Personal marijuana possession and home cultivation of marijuana has been legal in Virginia since 2021, but then-Gov. Glenn Youngkin (R) twice vetoed bills to provide consumers with a way to legally purchase regulated adult-use cannabis. Here are the key details of the new cannabis plan in the budget and how it compares to legislation that Spanberger vetoed—SB 542 and HB 642—as well as her previously proposed amendments to those measures: Adults will be able to purchase up to 2 ounces of marijuana in a single transaction, or up to an equivalent amount of other cannabis products as determined by regulators. That will represent an increase from the limit in current law of 1 ounce. Lawmakers previously proposed setting the amount at 2.5 ounces and the governor only wanted 2 ounces. Legal sales can begin on July 1, 2027. Lawmakers previously set the date for January 1, 2027, but the governor wanted it pushed back to July 1. There will be an excise tax of 6 percent on cannabis sales as well as a 5.3 percent retail sales and use tax, and municipalities will be allowed to set an additional local tax of up to 3.5 percent. Starting on July 1, 2029, the state excise tax will increase to 8 percent, in line with the governor’s previously proposed amendments. Revenue will be distributed to the Cannabis Equity Reinvestment Fund, early childhood education, the Department of Behavioral & Developmental Health Services and public health initiatives. The earlier measure passed by lawmakers would have allocated specific percentages to each, but the new language doesn’t specify what portion of revenue will go to each program. The governor, in her amendments, wanted to put all revenue into the general fund while earmarking it “for purposes such as early childhood education, behavioral health, public health awareness, prevention, treatment, and recovery services, workforce development, reentry, indigent criminal defense, and targeted reinvestment in historically disadvantaged communities.” Her amendment also sought to eliminate support for the Cannabis Equity Reinvestment Fund. The Virginia Cannabis Control Authority will oversee licensing and regulation of the new industry, and will also take on oversight of hemp, which is currently under the Department of Agriculture and Consumer Services. The body will be governed by a five-member board of directors appointed by the governor, whereas the bill previously passed by lawmakers contemplated a seven-member body with four appointed by the governor, two appointed by the speaker of the House and one appointed by the Senate Rules Committee. The definition of what constitutes a legal hemp product will be narrowed by removing a provision from current law that allows those containing more than 2 milligrams of total THC per package if they also have a ratio of CBD to THC that is 25:1 or more. Up to 350 retail marijuana stores will be allowed to be licensed to operate across the state, the same number that lawmakers had approved and greater than the 200 the governor had proposed. Local governments will not be able to opt of allowing marijuana businesses to operate in their area. Delivery services will be allowed. Serving sizes will be capped at 10 milligrams THC, with no more than 100 mg THC per package. Public use of marijuana will be a civil violation punishable by a $250 fine. That is ten times more than the $25 fine under current law, but less harsh than the class 4 criminal misdemeanor crime the governor had proposed. Possession of cannabis by people under the age of 21 will be punishable by a $25 fine and mandatory participation in a substance abuse treatment or education program or both. The governor had suggested treating underage possession as a class 1 misdemeanor, punishable with a mandatory minimum fine of $500 or 50 hours of community service, as well as the suspension of drivers licenses for at least six months. Existing medical cannabis operators can enter the adult-use market if they pay a $10 million licensing conversion fee. Cannabis businesses will have to establish labor peace agreements with workers. A legislative commission will be directed to study adding on-site consumption licenses and microbusiness cannabis event permits that would allow licensees to conduct sales at venues like farmers markets or pop-up locations. That provision was also included in the earlier legislation lawmakers passed but was suggested for deletion by the governor. Meanwhile, the governor signed several other reform bills this session—including measures to provide resentencing relief for people with past cannabis convictions, protect the parental rights of marijuana consumers and allow patients to access medical cannabis in hospitals. The post Virginia Officials Launch Marijuana Survey To Inform Drafting Of Rules For Newly Legalized Market appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net